Paige
Digital pathology AI applications for cancer pathology, including Paige Prostate.
Last updated: June 5, 2026
Back to directoryPrecision pathology software company offering AI image-analysis workflows, IVDR-certified diagnostic APPs, research tools, and integration paths with pathology platforms.
Labs and research teams evaluating AI-assisted biomarker scoring, tissue quantification, companion-diagnostic support, and interoperable pathology image analysis.
Compare within workflow: Digital pathology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Visiopharm as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat each APP independently because diagnostic, IVDR-certified, CE-IVD, RUO, EU/UK, U.S., and partner-integration status can differ by use case. |
|---|---|
| Privacy | Verify data-processing agreements, customer-data roles, image storage, cloud or local deployment, research-data sharing, access controls, retention, and partner-platform data paths. |
| Evidence | Review APP-level validation for tissue, stain, biomarker threshold, scanner, laboratory population, performance evaluation, and post-market follow-up before clinical use. |
| Workflow | Best used where AI outputs remain reviewable inside existing pathology platforms and where lab teams can govern APP selection, batch processing, QA, and signout. |
Visiopharm describes AI-driven precision pathology software for research and diagnostics, including IVDR-certified CE-IVD diagnostic APPs, research image-analysis tools, and integration workflows with image-management systems; its privacy policy describes customer and website data processing separately from deployment-specific diligence.
Not for: Applying CE-IVD or IVDR claims outside the exact APP, region, tissue, biomarker, scanner, and intended-use scope.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.